# FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy Subjects

> **NCT05905913** · PHASE1 · COMPLETED · sponsor: **Antabio** · enrollment: 72 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** ANT3310
- **DRUG:** ANT3310-placebo
- **DRUG:** ANT3310
- **DRUG:** ANT3310-placebo
- **DRUG:** ANT3310-placebo
- **DRUG:** ANT3310
- **DRUG:** Meropenem
- **DRUG:** Meropenem-placebo

## Key facts

- **NCT ID:** NCT05905913
- **Lead sponsor:** Antabio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-12
- **Primary completion:** 2024-01-05
- **Final completion:** 2024-01-05
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2024-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05905913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05905913, "FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy Subjects". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT05905913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*